Key Points
- Insider sale: Brian Savage sold 1,127 shares of TEVA on March 5 at an average price of $31.67 for proceeds of $35,692, reducing his holding to 10,914 shares (a 9.36% decrease).
- Wider insider selling: Several senior executives — including CEO Richard D. Francis (20,025 shares) and other officers — reported sizable sales at the same average price, a development some investors may view negatively.
- Solid fundamentals and guidance: Teva beat Q4 expectations (EPS $0.96 vs. $0.65; revenue $4.71B vs. $4.36B), issued FY‑2026 EPS guidance of 2.570–2.770, and has seen analysts raise targets, leaving a consensus rating of "Moderate Buy" (avg. target ~$37.67).
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Brian Savage sold 1,127 shares of the business's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares in the company, valued at $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Teva Pharmaceutical Industries Trading Up 1.3%
Shares of NYSE:TEVA opened at $31.44 on Tuesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock has a market capitalization of $36.15 billion, a price-to-earnings ratio of 26.20, a PEG ratio of 10.39 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35. The company has a 50 day moving average price of $33.01 and a 200 day moving average price of $26.41.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion for the quarter, compared to analysts' expectations of $4.36 billion. During the same quarter in the prior year, the company earned $0.71 earnings per share. The firm's revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.
Key Stories Impacting Teva Pharmaceutical Industries
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Q4 results and FY‑2026 guidance remain a tailwind — Teva posted an EPS and revenue beat for the most recent quarter and set FY‑2026 EPS guidance of 2.570–2.770, with year‑over‑year revenue growth of ~11.4%. Those fundamentals help explain the stock’s strength today. MarketBeat TEVA coverage
- Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference — a verbatim transcript of the presentation is available; investor focus will be on any pipeline updates, margin commentary or capital allocation remarks that could support the company’s outlook. Leerink presentation transcript
- Negative Sentiment: Significant insider selling disclosed (March 5 filings) — multiple executives sold shares at an average price of $31.67, including CEO Richard D. Francis (20,025 shares), EVP Richard Daniell (17,295), Placid Jover (14,150), Eric A. Hughes (9,533), Christine Fox (7,924) and Brian Savage (1,127). These disclosed sales reduce insider positions and may be read negatively by some investors; supporting SEC filings are available. Example SEC filing (CEO sale)
- Negative Sentiment: Media coverage highlights large CEO share sales — an American Banking News story flagged substantial CEO selling, which can amplify investor caution even when sales are routine or pre‑planned. Insider selling article
Analysts Set New Price Targets
Several equities research analysts have recently commented on TEVA shares. Scotiabank upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a report on Thursday, January 29th. Barclays lifted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a research note on Friday, January 30th. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 31st. Finally, The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $37.67.
Read Our Latest Research Report on TEVA
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $25,000. Allworth Financial LP boosted its position in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after acquiring an additional 329 shares during the period. Grove Bank & Trust grew its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after purchasing an additional 345 shares during the period. Finally, Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 54.05% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
